No Data
No Data
Kexing Pharmaceuticals (688136.SH): A total cost of 31.12 million yuan to buy back 0.94% of shares
Gelonghui, May 21丨Kexon Pharmaceuticals (688136.SH) announced that as of the disclosure date of this announcement, the company's share repurchase period has expired, the company's cumulative repurchase amount through centralized bidding transactions has reached the lower limit of the repurchase amount, and the implementation of this share repurchase plan has been completed. The company has repurchased 1,880,572 shares of the company's shares through the Shanghai Stock Exchange trading system, accounting for 0.94% of the company's total share capital. The highest price of the repurchase transaction was 19.95 yuan/share, the lowest price was 14.30 yuan/share, the average repurchase price was 16.55 yuan/share, and the total amount of capital paid
Kexing Biopharm-Anlage Besteht EU-GMP-Zertifizierung Für Paclitaxel Zur Injektion (Albumin Gebunden)
SHENZHEN, China, 10. Mai 2024 /PRNewswire/ -- Am Abend des 5. Mai hat Kexing Biopharm (Aktiencode: 688136) bekanntgegeben, dass das Unternehmen von der norwegischen Arzneimittelbehörde gemäß den Vo
Kexing Biopharm Obtiene La Certificación GMP De La UE Para Paclitaxel Inyectable (Unido a Albúmina)
SHENZHEN, China, 10 de mayo de 2024 /PRNewswire/ -- En la tarde del 5 de mayo, Kexing Biopharm (código bursátil: 688136) anunció que había obtenido un "Certificado de Conformidad GMP de un Fabric
Kexing Biopharm Facility Passes EU GMP Certification for Paclitaxel for Injection (Albumin Bound)
SHENZHEN, China, May 10, 2024 /PRNewswire/ -- On the evening of May 5, Kexing Biopharm (stock code: 688136) announced it had obtained a "Certificate of GMP Compliance of a Manufacturer" granted by th
Kexon Pharmaceuticals (688136): The pace of GMP factory inspections in many countries is in line with expectations, and the EU is more certain that Bai Zi will go overseas
Ping An's view: The EU market space pattern is good, and the company's peak sales volume in the EU is expected to exceed 700 million yuan. According to the company's announcement, by the end of 2023, the 12 products introduced by the company had signed contracts with customers in more than 40 countries and one after another
Kexing Pharmaceuticals (688136) Company Brief Review Report: Domestic business is stable and waiting for breakthroughs in internationalization
Incident: The company released its 2023 annual report. In 2023, it achieved operating income of 1,259 million yuan (-4.32%), net profit to mother of -190 million yuan, and net profit of non-return to mother of -210 million yuan. 202
No Data